Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calcifediol extended release - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma

Drug Profile

Calcifediol extended release - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma

Alternative Names: CTAP-101; CTAP101 Capsules; Modified-release calcifediol - OPKO Renal/Vifor Fresenius Medical Care Renal Pharma; RAYALDEE; Rayaldee; Rayaldy

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytochroma
  • Developer OPKO Renal; Vifor Fresenius Medical Care Renal Pharma
  • Class Calcium regulators; Osteoporosis therapies; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Secondary hyperparathyroidism
  • Phase I Bone disorders

Most Recent Events

  • 20 Aug 2018 OPKO Ireland Global Holdings initiates a phase I trial in Healthy volunteers in USA (NCT03660800)
  • 03 Aug 2018 Chemical structure information added
  • 18 Jul 2018 Phase-I development in Bone-disorders (Adjunctive treatment, Prevention) in USA (PO, Capsule) (NCT02274623)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top